Chimeric Therapeutics Ltd (chm) Logo

Chimeric Therapeutics Ltd (CHM)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

CHM Chart

Snapshot

CHM's Principal Activity is the developing CAR T cell therapies for tumors based on research at the City of Hope Cancer Centre in Los Angeles.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -60.91%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,454 of 2,416
Sector Rank 125 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies LDX / AGH / CDX
EPS -$0.077
DPS $0.00
Book Value Per Share $0.07

Broker Consensus

CHM is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Chimeric Therapeutics Limited (CHM) is a biotechnology company developing a breakthrough cancer cell therapy drug which was discovered at the prestigious City of Hope Cancer Centre in Los Angeles, California. CHM is developing ground breaking CAR T cell therapy.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Carlton South VIC 3053
Website www.chimerictherapeutics.com
Registry BoardRoom
Auditor Grant Thornton Audit Pty Ltd
Date Listed 18 Jan 2021

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
28/09/2022 Report (Annual)
27/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Jennifer Chow Chief Executive Officer,Managing Director Aug 2021

Ms Jennifer Chow

Chief Executive Officer,Managing Director

Ms Chow has more than 20 years of commercial strategy and marketing experience focused on cellular therapy, hematology and oncology. Prior to joining Chimeric, Ms Chow was Head of Global Marketing, Analytics and Commercial Operations at global CAR T company Kite Pharmaceuticals (acquired by Gilead Sciences in 2017). She was previously Global Cell Therapy Commercial Lead at Celgene Corporation and was responsible for designing and developing the global CAR T commercial strategy and operating model. Ms Chow was also formerly at Roche, Nycomed/Takeda and Schering Canada.

Dr George Matcham Non-Executive Director Jul 2021

Dr George Matcham

Non-Executive Director

Dr Matcham has experience in the biopharma sector, following worked for three decades with cell therapy giant Celgene Corporation. He joined Celgene in its infancy in 1988 when the company was a 30-person startup, retiring in 2018. At Celgene, Dr Matcham championed the introduction of cellular immunotherapy and led the establishment of cell therapy and biologics technical development. At Celgene, Dr Matcham held several senior positions, including Chief Operations Officer of Celgene Cellular Therapeutics and Senior Vice President of CAR T CMC Development, where he oversaw clinical supply. In recent years, Dr Matcham has also served on the board and as an advisor at Instil Bio throughout its financing rounds and IPO.

Ms Cynthia Elkins Non-Executive Director Feb 2021

Ms Cynthia Elkins

Non-Executive Director

Ms Elkins has over 30 years' experience in biotechnology and high tech in the US at Ariba, Genentech (member of the Roche group), Juno Therapeutics. She created the Global Cell Therapy Patient Experience including all patient operations and digital platform while at Juno/Celgene/BMS. Ms Elkins' sector experience includes autologous cell therapy and biooncology. She also has experience in acquisitions/integrations and utilizing technology to create digitally connected communities. She is Chair of The Foundation for Art & Healing (The UnLonely Project), since July 2019. She is Member of Risk Committee.

Ms Leslie (Mi Ok) Chong Non-Executive Director Aug 2020

Ms Leslie (Mi Ok) Chong

Non-Executive Director

Ms Chong has over 23 years' experience in leading clinical and department development in oncology. Currently Ms Chong is the CEO and Managing Director of a clinical stage immuno-oncology company called Imugene Limited. Previously Ms Chong worked as a Senior Clinical Program Lead at Genetech, a member of the Roche family, in the head office in San Francisco. She is Director of Cure Brain Cancer Foundation (non-profit organisation), since April 2020. She is Chair of Risk Committee.

Dr Lesley Russell Non-Executive Director Aug 2020

Dr Lesley Russell

Non-Executive Director

Dr Russell has over 25 years' experience and leadership in the international pharmaceutical field as a chief medical officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Dr Russell is Director of Enanta Pharmaceuticals, since November 2016 and Imugene Limited, since 23 April 2019. Dr Russell is Member of Risk Committee.

Mr Paul Alex Hopper Founder,Executive Chairman,Executive Director Feb 2020

Mr Paul Alex Hopper

Founder,Executive Chairman,Executive Director

Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies both as chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas of immunotherapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. He is Director of Imugene Limited, since 31 October 2012 SUDA Pharmaceuticals Ltd, since 15 May 2019 and Scopus BioPharma Inc (New York) (Stat3 technology), since December 2020.

Mr Nathan Jong Joint Company Secretary N/A
Mr Phillip Hains Chief Financial Officer,Joint Company Secretary N/A
Syed Rizvi Chief Medical Officer N/A

Director Transactions

CHM directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
25/03/22 Leslie (Mi Ok) Chong Issued 3,905 $0.15 $585 Rights issue
25/03/22 Leslie (Mi Ok) Chong Issued 3,905 $0.17 $663 Rights issue
25/03/22 Paul Hopper Issued 2,941,176 $0.15 $441,176 Rights issue
25/03/22 Cynthia Elkins Issued 7,873 $0.15 $1,180 Rights issue
25/03/22 Cynthia Elkins Issued 7,873 $0.17 $1,338 Rights issue
25/03/22 George Matcham Issued 158,730 $0.017 $2,698 Rights issue
25/03/22 George Matcham Issued 158,730 $0.15 $23,809 Rights issue
25/03/22 George Matcham Transfer 500,000 $0.15 $75,000 Off-market transfer
25/03/22 George Matcham Transfer 500,000 $0.15 $75,000 Off-market transfer
01/03/22 Paul Hopper Issued 2,941,176 $0.17 $499,999 Rights issue
03/12/21 George Matcham Issued 2,750,000 $0.26 $715,000 Issue of options
03/12/21 Cynthia Elkins Issued 2,750,000 $0.26 $715,000 Issue of options
03/12/21 Jennifer Chow Issued 2,000,000 $0.26 $520,000 Issue of options
03/12/21 Jennifer Chow Issued 1,032,416 $0.272 $280,817 Issue of securities
03/12/21 Paul Hopper Buy +375,000 $0.262 $98,437 On-market trade
04/08/21 George Matcham Buy +500,000 $0.332 $166,000 On-market trade
08/03/21 Cynthia Elkins Buy +24,800 $0.318 $7,881 On-market trade
29/01/21 Leslie (Mi Ok) Chong Buy +7,300 $0.326 $2,378 On-market trade
20/01/21 Leslie (Mi Ok) Chong Buy +5,000 $0.39 $1,950 On-market trade

Director Interests

The current holdings of CHM directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
George Matcham 25/03/2022 0 658,730 2,908,730 N/A
Cynthia Elkins 25/03/2022 0 32,673 2,757,873 N/A
Paul Hopper 25/03/2022 375,000 80,718,954 2,941,176 N/A
Leslie (Mi Ok) Chong 25/03/2022 16,205 N/A 2,753,905 N/A
Jennifer Chow 03/12/2021 1,702,914 N/A 10,291,495 N/A
Lesley Russell 30/06/2021 N/A N/A 2,750,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Sep 17, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Moreglade Pty Limited 77,777,778 23.33%
City Of Hope 11,966,649 3.59%
Christine Brown 11,696,565 3.51%
Michael E Barish 11,522,634 3.46%
HSBC Custody Nominees (Australia) Limited A/C 2 10,662,042 3.20%
Citicorp Nominees Pty Limited 9,694,101 2.91%
Brispot Nominees Pty Ltd <House Head Nominee A/C> 5,409,422 1.62%
Zerrin Investments Pty Ltd 4,800,001 1.44%
HSBC Custody Nominees (Australia) Limited 4,253,123 1.28%
Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C> 3,750,000 1.12%
UBS Nominees Pty Ltd 3,475,000 1.04%
Mr Lisheng Wang 3,165,429 0.95%
Jarl Mohn <The Mohn Family A/C> 2,304,527 0.69%
Australian Direct Investments Pty Limited <The Adi Super Fund A/C> 2,304,527 0.69%
Liberty National Pty Ltd <Liberty National Family A/C> 2,000,000 0.60%
Marshall Super Fund Pty Ltd <J Marshall Super Fund A/C> 1,800,000 0.54%
Mr Duncan Gerard Gowans & Mrs Jodie Louise Gowans <Gowans Superfund A/C> 1,725,000 0.52%
Kamala Holdings Pty Ltd <The Kamala 1994 S/F A/C> 1,616,667 0.48%
Mr Tim Bensley & Ms Jenny Jiaer Zhang 1,340,000 0.40%
Mrs Anna Felicia Belton 1,320,000 0.40%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 32 1,119 707 1,648 315 3,821

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Paul Hopper 01/03/2022 81,093,954 21.40

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
01-03-22 Paul Hopper 2,941,176 23.29 21.40

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
03-12-21 Paul Hopper 4,234,052 24.9 23.3

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.285 30 June
CHM Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.